Merck drug raltegravir shows good results as part of combination therapy

Australian researchers urge HIV-positive people on antiretrovirals to continue practising safe sex

Starpharma's anti-HIV and herpes microbicide is well tolerated by men, the company told the IAS conference today.

Immune deficiency suspected in higher cancer risk levels.

Melbourne immunotherapy developer Virax Holdings (ASX:VHL) has raised $3.1 million through a rights issue for the further development of its HIV therapeutic vaccine, falling $700,000 short of the $3.8 million the company planned to raise.

Melbourne immunotherapy developer Virax Holdings (ASX:VHL) has lodged a prospectus to raise AUD$3.85 million through a rights issue for the further development of its HIV therapeutic vaccine VIR201 following its unsuccessful bid for US NIH funding.

Narhex Life Sciences (ASX:NLS) has formed a new scientific advisory board, following Prof John Mills' appointment last week as managing director, replacing founder John Majewski, and the relocation of the company's head office to Melbourne.

University of NSW epidemiologists have uncovered evidence for an unexpected upside to allergies -- people who suffer from asthma and hay fever are 50 per cent less likely to develop non-Hodgkin's lymphoma.

Results from a Phase I/IIa study of an experimental HIV therapeutic vaccine developed by on Melbourne company Virax have generated interest from researchers at an international conference of HIV and AIDS researchers in San Francisco, according to the trial's coordinator.